Ten years ago, when Josh Makower, MD, started an incubator, ExploraMed Inc., it was arguably the device industry's first. Makower proposed a different model for device company creation: to begin without a clear idea of the business, but, backed by some money and a vision of the clinical need, to search for the right technology to address that need. Now, a year after selling one of the incubator's start-ups, TransVascular, to Medtronic, Makower has resurrected ExploraMed, and he's just funded his first company. While the model remains largely the same, subtle differences between ExploraMed I and ExploraMed II highlight how much the medical device start-up world has changed over the past decade.
Ten years ago, Josh Makower, MD, started an incubator,
ExploraMed Inc. , arguably the device
industry's first, at a time when few people in the medical device
industry felt there was any need for incubators. After all, device
company creation was roaring ahead, backed by an eager venture
capital community just discovering medical technology and a public
investor market that was eagerly embracing the promise implicit in
the products that device companies offered.
Over the next several years, however, ExploraMed and the device start-up community went in somewhat separate directions. While the incubator...
The Santreva-ATK system integrates axial plaque traversal, lateral plaque compression and channel formation into a single mechanism, simplifying procedures that previously required sequential steps. The system directs the physician’s energy toward the plaque while protecting the vessel wall.
Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.
Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.
Dexcom has endured recalls, layoffs and leadership change, but interim CEO Jake Leach said the company remains committed to innovating next-gen devices.
The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.
Confido Health has raised $10m in Series A funding to expand its AI voice agent from patient scheduling into referrals, prescriptions and billing, bringing the total collected to $13m. CEO Chetan Reddy predicts in the next decade, AI use for admin tasks in healthcare will become mainstream.
Dexcom has endured recalls, layoffs and leadership change, but interim CEO Jake Leach said the company remains committed to innovating next-gen devices.
